MedPath

Minimization of Intradialytic Hypotension Using Cardiography-Guided Intervention

Phase 4
Conditions
Intradialytic Hypotension
Interventions
Device: pressure stockings
Other: pressure stockings and midodrine
Registration Number
NCT03080441
Lead Sponsor
Nimedical
Brief Summary

This is a research study to test the application of FDA-approved, non-invasive device (NICaS) that measure the performance of your heart during HD treatment.

Detailed Description

The incidence of intradialytic hypotension (IDH) events, reported to occur in 15% to 50% of hemodialysis (HD) treatments, is still high despite major technical advances in HD technology. By definition, excessive reduction in intravascular volume by ultrafiltration and limited vascular refilling from tissues into the vascular space is the cause of IDH. Chronic HD patients exhibit a high prevalence of peripheral vascular and cardiac abnormalities. Specifically, hemodynamic instability during HD can occur due to insufficient reduction in venous unstressed volume, poor diastolic filling under reduced atrial pressures associated with diastolic dysfunction, altered cardiac contractility, and impaired vascular reactivity. An IDH event can lead to myocardial cerebral and other organ ischemia. Long- and short-term adverse outcomes have been associated with IDH, a common HD complication and significant cause of morbidity.

Recent pilot studies suggest that in IDH-prone subjects, measurements of hemodynamic variables during HD can be used to categorize the hemodynamic response into three subgroups: cardiac power index (CPI) reduction with stable total peripheral resistance (TPR), TPR reduction with stable CPI, and reduction in TPR and CPI groups. It is hypothesized that targeted intervention for each subgroup can reduce IDH.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
35
Inclusion Criteria
  • 18 years old or older
  • Have been on maintenance hemodialysis at the facility for at least six months
  • Have not had un-excused missed treatments for six months
  • Is symptomatic to HD treatments
  • Males and non-pregnant/non-nursing females, as confirmed via urine pregnancy testing of women of child bearing potential
Exclusion Criteria
  • Patient refusal
  • Currently on Midodrine at the start of the Phase 1, Observation period
  • Any known contraindications to Midodrine

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Phase 1 Group 1pressure stockingspressure stockings worn during dialysis treatment
Phase 1 Group 2MidodrineMidodrine before dialysis treatment
Phase 1 Group 3pressure stockings and midodrinepressure stocking and Midodrine
Primary Outcome Measures
NameTimeMethod
Hypotension6 weeks

Post dialysis BP measured in mm/Hg

Weight6 weeks

Post dialysis weight measure in kg

Cardiac Index1 week

Cardiac Index results from NICaS results vs Echocardiogram results measured in L/min/m2

Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath